Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover
Wins Three-Horse Race With Sanofi And J&J
The US major has announced its biggest acquisition to date in the form of a takeover that should expand its rare disease franchise and stave off concerns about internal products facing biosimilar competition.
